These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Broze GJ; Girard TJ; Novotny WF Biochemistry; 1990 Aug; 29(33):7539-46. PubMed ID: 2271516 [No Abstract] [Full Text] [Related]
9. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Wesselschmidt R; Likert K; Girard T; Wun TC; Broze GJ Blood; 1992 Apr; 79(8):2004-10. PubMed ID: 1562726 [TBL] [Abstract][Full Text] [Related]
10. [Tissue factor pathway inhibitor (TFPI) and its role in pathology]. Rucińska M; Gacko M; Skrzydlewski Z Postepy Hig Med Dosw; 1997; 51(4):421-30. PubMed ID: 9446103 [TBL] [Abstract][Full Text] [Related]
11. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. Novotny WF; Girard TJ; Miletich JP; Broze GJ J Biol Chem; 1989 Nov; 264(31):18832-7. PubMed ID: 2553722 [TBL] [Abstract][Full Text] [Related]
12. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: evidence for a two-step model of inhibition. Warn-Cramer BJ; Rao LV; Maki SL; Rapaport SI Thromb Haemost; 1988 Dec; 60(3):453-6. PubMed ID: 3238648 [TBL] [Abstract][Full Text] [Related]
13. Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor. Lindhout T; Franssen J; Willems G Thromb Haemost; 1995 Sep; 74(3):910-5. PubMed ID: 8571320 [TBL] [Abstract][Full Text] [Related]
14. Extrinsic pathway inhibitor (EPI) released to the blood by heparin is a more powerful coagulation inhibitor than is recombinant EPI. Lindahl AK; Abildgaard U; Larsen ML; Staalesen R; Hammer AK; Sandset PM; Nordfang O; Beck TC Thromb Res; 1991 Jun; 62(6):607-14. PubMed ID: 1926055 [TBL] [Abstract][Full Text] [Related]
15. Tissue factor pathway inhibitor; its structure, function and clinical significance. Kato H Pol J Pharmacol; 1996; 48(1):67-72. PubMed ID: 9112630 [TBL] [Abstract][Full Text] [Related]
16. Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8. Cunningham AC; Hasty KA; Enghild JJ; Mast AE Biochem J; 2002 Oct; 367(Pt 2):451-8. PubMed ID: 12117418 [TBL] [Abstract][Full Text] [Related]
17. Functional properties of factor VIIa/tissue factor formed with purified tissue factor and with tissue factor expressed on cultured endothelial cells. Almus FE; Rao LV; Rapaport SI Thromb Haemost; 1989 Dec; 62(4):1067-73. PubMed ID: 2617454 [TBL] [Abstract][Full Text] [Related]
18. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Wesselschmidt R; Likert K; Huang Z; MacPhail L; Broze GJ Blood Coagul Fibrinolysis; 1993 Oct; 4(5):661-9. PubMed ID: 8292716 [TBL] [Abstract][Full Text] [Related]
19. Tissue factor pathway inhibitor (TFPI). Rucińska M; Gacko M; Skrzydlewski Z Rocz Akad Med Bialymst; 1997; 42 Suppl 1():118-22. PubMed ID: 9337530 [TBL] [Abstract][Full Text] [Related]